Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

493.22
+10.152.10%
Pre-market: 496.002.78+0.56%04:40 EDT
Volume:1.50M
Turnover:740.33M
Market Cap:53.27B
PE:12.51
High:499.88
Open:485.54
Low:485.00
Close:483.07
Loading ...

Regeneron Shares Extend Premarket Fall; Last Down 11.7%

THOMSON REUTERS
·
30 May

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

Dow Jones
·
30 May

Regeneron Shares Fall 8.2% Premarket; Co and Sanofi's Drug Itepekimab Met Main Goal in One Out of Two Late-Stage Trials

THOMSON REUTERS
·
30 May

Regeneron: Strong Financial Performance and Strategic Initiatives Drive Buy Rating with USD700 Target Price

TIPRANKS
·
30 May

BRIEF-Sanofi's AERIFY-1 Met Primary Endpoint, AERIFY-2 Did Not

Reuters
·
30 May

Sanofi Announces Mixed Results from Phase 3 Studies of Itepekimab for COPD Treatment

Reuters
·
30 May

Regeneron Pharmaceuticals Inc - Regeneron and Sanofi Are Assessing This Data and Will Discuss Next Steps With Regulatory Authorities

THOMSON REUTERS
·
30 May

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

GlobeNewswire
·
30 May

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
30 May

Regeneron Pharmaceuticals' Itepekimab Likely to Open 'Large' Market Opportunity, RBC Says

MT Newswires Live
·
29 May

Telesis Bio Secures Licensing Deal with Regeneron for On-Site DNA Synthesis Platform

Reuters
·
28 May

Regeneron (REGN) Gets a Buy from BMO Capital

TIPRANKS
·
28 May

Regeneron Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
28 May

Regeneron Pharmaceuticals' True Value Masked by Eylea Concerns, RBC Says

MT Newswires Live
·
27 May

Regeneron Pharma Price Target Maintained With a $943.00/Share by RBC Capital

Dow Jones
·
27 May

Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals

Reuters
·
23 May

Strokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them. -- Barrons.com

Dow Jones
·
23 May

BRIEF-Linvoseltamab In Combination With Carfilzomib Or Bortezomib Shows Promising Initial Results In Earlier Lines Of Treatment For Relapsed/Refractory Multiple Myeloma

Reuters
·
23 May

Regeneron Pharmaceuticals Reveals Trial Data of Drug Combination to Treat Multiple Myeloma

MT Newswires Live
·
23 May

Regeneron announces initial results from two cohorts of LINKER-MM2 trial

TIPRANKS
·
23 May